NIH is the nation's medical research agency – making important medical discoveries that improve health and save lives.
NIH is still recruiting RSD/CRPS patients to complete the clinical trial with Neurotropin. Recently, the inclusion criteria of study patients have been modified. Below is an updated study announcement. Potential candidates for the study are being recruited.
Clinical trial for the treatment of early CRPS I and II
(Complex Regional Pain Syndromes I and II or
Reflex Sympathetic Dystrophy and Causalgia)
A National Institutes of Health Study
A collaborative study (NIH Protocol # 00-NR-0200) involving investigators in the National Institute of Neurological Disorders and Stroke, National Institute of Dental and Craniofacial Research, Rehabilitation Medicine Department, and National Institute of Nursing Research at NIH, is being initiated to examine the use of Neurotropin to treat Complex Regional Pain Syndromes I and II (CRPS I and II). These disorders were formerly known as Reflex Sympathetic Dystrophy (RSD) and Causalgia. Neurotropin is a medication that is currently used in Japan to treat RSD and other painful conditions. The admission criteria for this initial study have recently been amended to include patients who developed pain in one limb that has been diagnosed as having CRPS I or II for more than 2 weeks. Subjects are now being recruited for this outpatient, double blind, placebo-controlled cross-over study. The study requires 11-12 weeks with 3 or 4 short visits to the NIH Clinical Center. Eligible patients will be reimbursed for travel and other expenses, continue on their current medications as well as the experimental agents and will receive optimal medical care at no cost. The patient and/or the patient’s physician should contact the NIH at the address listed below. Upon completion of the study the patient’s physician will receive a report of the results of the study and recommendations for future treatment, as necessary.